Ansuvimab-zykl: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 April 2025

  • curprev 14:5614:56, 27 April 2025 Alara E. Dagsali talk contribs 18,021 bytes +18,021 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Ebanga |aOrAn=a |drugClass=ebolavirus (EBOV) glycoprotein 1 (GP1)-directed recombinant, human Immunoglobulin G1 (IgG1) monoclonal antibody. |indicationType=treatment |indication=of infection caused by Orthoebolavirus zairense(formerly Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection..."
Retrieved from "https://www.wikidoc.org/index.php/Ansuvimab-zykl"